Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2008

View Archived Issues

NeuroHealing receives grant from FDA for development of NH-001

Adjuvanted DNA vaccination against H5N1 influenza induces antibody response

Experimental lupus improved by bortezomib treatment

New anticancer agents described in recent patent literature

Phase II study of MBP-8298 clears DSMB review

Irribow approved in Japan for irritable bowel syndrome in men

Astellas Pharma's Graceptor approved in Japan for prevention of organ rejection

Nasonex receives Japanese approval for treatment of allergic rhinitis in adults

Raptor enters collaboration with UC for phase IIa clinical trial of cysteamine in NASH

Novartis to initiate phase III trial of Antisoma's ASA-404 in NSCLC

EpiCept and GNI enter license agreement for EP-1013

Boehringer licenses drug targets under autoimmune collaboration with Galapagos

MRCT and Biolex successfully complete collaboration to humanize BLX-301

sanofi-aventis to collaborate with Johns Hopkins University on respiratory diseases

ImmuneRegen reports results from genotoxicity studies of Homspera

Roche's novel Aurora kinase inhibitor shows promising preclinical profile

U.K. Ministry of Defense to initiate animal efficacy studies of ALS-886 in lung injury

Study investigates cardiac safety profile of antimuscarinic drugs for overactive bladder

Bradmer reports progression-free survival data from phase II trials of Neuradiab in GBM

Biovest announces results for BiovaxID in non-Hodgkin's lymphoma trial

EMEA grants orphan medicinal product designation to ProtAffin's PA-401

Hemantane improves symptoms of Parkinson's disease in an open-label study

Merrion enters next stage of oral drug collaboration program with Novo Nordisk

Teva signs definitive agreement to acquire Barr

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...